Please login to the form below

Not currently logged in
Email:
Password:

Sanofi’s diabetes IMPACT programme wins at PMEA 2017

Takes home first place in Excellence in Demonstrating Economic and Societal Value

Sanofi

Sanofi celebrated a strong win last night at last night’s PMEA awards in London, earning a trophy in Excellence in Demonstrating Economic and Societal Value for its diabetes campaign.

‘IMPACT’, which was described by PMEA’s judges as “ambitious yet successful”, made a case for better diabetes control as the disease costs the NHS around £10bn annually.

The programme - which Sanofi worked on in collaboration with Diabetes UK and JDRF, a type 1 diabetes charity - went on to describe that 80% of these costs attribute to treating complications, which could potentially be reduced through improved blood glucose control.

PMEA’s judges said: “What was really impressive about this integrated project is that Sanofi successfully partnered with leading health economic groups.

“This programme was clearly articulated and coherent to resonate with all stakeholders.”

Run by PMLiVE’s publisher the PMGroup, PMEA exists to reward responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes.

The programme has been specifically designed to recognise and commend excellence, best practice and innovation in local, European and international markets.

* See all the results from PMEA 2017

* View the PMEA 2017 photo gallery

Article by
Gemma Jones

16th November 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics